An implantable device configured to be deployed at a deployment site such as across a body passage. The implantable device has features enhancing the resistance of at least a portion of the implantable device to migration from the deployment site. The implantable device may have surfaces contacting tissue at the deployment site which are configured to promote tissue ingrowth with respect to the implantable device. Surfaces of the implantable device not contacting tissue may be enlarged and coated with a coating material increasing the strength of the coated portions of the implantable device to resist migration of the implantable device with respect to the deployment site.

Devices and methods can be used for the endoscopic treatment of conditions such as obesity and metabolic diseases. For example, this document provides devices and methods for bypassing portions of the GI tract that can reduce nutritional uptake, decrease weight, and improve diabetes control. The devices are advantageously designed for migration resistance, reflux prevention, and ease of implantation.

An volume filling device for treatment of obesity is placed outside the stomach wall of the patient to reduce the inner volume of the stomach, thereby affecting the patient's appetite. By providing the volume filling device outside the stomach wall, contact with stomach acids is avoided, thereby increasing the life of the device.

The present invention relates to gastric obstruction device deployment systems and a device for intermittently obstructing a bodily opening, such as a gastric opening, and includes a proximal occluding member connected to a distal occluding member by a tether. The proximal occluding member is formable from an elongated and narrower configuration to a contracted or expanded but wider configuration. When employed in the stomach, the gastric obstruction device may be arranged transluminally with the distal occluding member disposed in the duodenum and the proximal occluding member disposed against the pyloric valve, intermittently occluding the pyloric valve and preventing or delaying the flow of gastric contents through the pyloric valve.

The present disclosure relates to an implantable device having a frame and a flow restrictor. The frame includes a central portion and an end portion on either end of the frame. The flow restrictor is disposed within a lumen of the frame. The flow restrictor is configured to transition between a collapsed configuration and a deployed configuration. The flow restrictor may include a porosity configured to reduce fluid flow through the flow restrictor without completely occluding fluid flow.

An intragastric device including (1) a first wire mesh structure having a pre-deployment shape, a post-deployment shape greater than the pre-deployment state, and one or more openings on an upper portion of the first wire mesh structure that are configured to permit food to enter the device, (2) a second wire mesh structure having a pre-deployment shape a post-deployment shape greater than the pre-deployment state, and one or more openings on a lower portion of the second wire mesh structure that are configured to permit food to exit the device. A sleeve may be coupled to the lower portion of the wire mesh structure. An anti-migration collar may interconnect the wire mesh structure and the sleeve. In use, food enters the upper portion of the first wire mesh structure, passes through both wire mesh structures, and then exits the lower portion of the second wire mesh structure.

An occlusion device having a lumen defined therethrough and a saddle narrower than saddles of prior occlusion devices or stents to allow provision of an occlusion element with respect to a portion of the saddle to occlude flow of materials through the saddle. The inner diameter of the narrowed saddle may be 6 mm or less. The occlusion element may be formed from a material which plugs a portion of the occlusion device lumen extending through the saddle and/or which restrains a portion of the saddle from expanding thereby occluding flow of materials therethrough. The remainder of the saddle and/or inwardly facing surfaces of at least one retention member extending outwardly along an end of the saddle may be configured to promote tissue ingrowth, such as by remaining uncoated.

An apparatus for the treatment of acid reflux disease comprising two or more movement restriction device segments adapted to be movement restriction device of a controlled size. The movement restriction device can at least partly be invaginated by a patient's stomach fundus wall. A substantial part of the outer surface of the movement restriction device is adapted to rest against the stomach wall without injuring the latter in a position between the patient's diaphragm and at least a portion of the lower part of the invaginated stomach fundus wall, such that movement of the cardiac notch of the patient's stomach towards the patient's diaphragm is restricted, to thereby prevent the cardia from sliding through the patient's diaphragm opening into the patient's thorax, so as to maintain the supporting pressure against the patient's cardia sphincter muscle exerted from the patient's abdomen.

The invention relates to an anchor (14) for an implant (20) for use in the gastro-intestinal tract. The anchor (14) comprises a tissue contact portion (16) with a bedding region (16a). The bedding region (16a) is configured to at least partly integrate into, or to promote integration into, a wall of the gastro-intestinal tract.

A gastroscopic method and instrument for treating obesity of a patient, using a device adapted to stretch a part of the stomach wall of said patient. The method comprises the steps of: inserting the device into the stomach through the esophagus, placing the device in contact with the stomach wall, and fixating the device to the stomach wall such that the device can stretch a part of the stomach wall.